Aktis Oncology, Inc.

NASDAQ:AKTS

Biotechnology

Healthcare
$16.10 +0.47%

+$0.11 today

Market cap
$865.32M
Beta
1.10
P/E (TTM)
-28.7
EPS (TTM)
-$0.82
52W Low $14.72High $29.16

Volume 0.44M

Average 0.33M

AKTS Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Aktis Oncology, Inc.NASDAQ: AKTS

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development of $20.04M in Q1 FY2026

Q1 FY2026 research & development was $20.04M. Over 3 fiscal years it compounded at +67.7% a year.

Context

  • Research & development amounted to 1038.2% of revenue in FY2025, down 1715.9 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$20.04M+21.5% QoQ
Last fiscal yearDec 2025
$67.45M+64.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+64.7%——
3-year CAGR+67.7%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
67.45M USD
Year-over-year change
+64.7%
3-year CAGR
+67.7%

Research & Development vs competitors

How AKTS compares with its peers on the latest reported figures

  • AKTS's FY2025 research & development of $67.45M is the lowest of the 6 companies compared; the peer median is $230.13M.
  • Its year-over-year change of +64.7% is the highest of 6, against a peer median of +17.2%.
  • Research & development amounts to 1038.2% of revenue for AKTS, versus a peer median of 86.2%.
AKTS Competitors Peer median
Research & Development for AKTS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMCRImmunocore Holdings plcLTM Mar 2026$259.11M +17.2%+34.4%67.2%
IMNMImmunome, Inc.LTM Sep 2026$236.54M +35.6%+95.7%—
BCYCBicycle Therapeutics plcLTM Mar 2026$230.13M +16.7%+43.3%362.4%
MGNXMacroGenics, Inc.LTM Mar 2026$135.36M -19.9%-12.2%86.2%
AURAAura Biosciences, Inc.LTM Mar 2026$94.92M +19.3%+28.8%—
AKTSAktis Oncology, Inc.FY2025$67.45M +64.7%+67.7%1038.2%
Peer median (excluding AKTS) $230.13M+17.2%+34.4%86.2%

Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue001.49M6.5M
Cost of Revenue0000
Gross Profit001.49M6.5M
Gross Margin——100.0%100.0%
Research & Development14.3M25.92M40.95M67.45M
Selling, General & Admin5.11M7.68M11.31M12.6M
Operating Expenses19.76M34.79M53.54M81.18M
Depreciation & Amortization445K1.2M1.58M2.33M
EBITDA(17.48M)(27.45M)(42.41M)(61.4M)
EBITDA Margin——-2851.7%-945.1%
Operating Income(19.76M)(34.79M)(52.05M)(74.68M)
Operating Margin——-3500.3%-1149.5%
Interest Income1.65M5.38M8.1M11.01M
Interest Expense0000
Other Income / Expenses1.84M6.15M8.07M10.95M
Income Before Tax(17.93M)(28.64M)(43.98M)(63.73M)
Pre-Tax Margin——-2957.6%-980.9%
Income Tax Expense0000
Net Income(17.93M)(28.64M)(43.98M)(63.73M)
Net Margin——-2957.6%-980.9%
EPS (Basic)(0.51)(0.82)(1.26)(1.19)
EPS (Diluted)(0.51)(0.82)(1.26)(1.19)
Weighted Avg Shares34.86M34.86M34.86M52.52M
Weighted Avg Shares (Diluted)34.86M34.86M34.86M52.52M

Aktis Oncology, Inc.

NASDAQ:AKTS

Intrinsic Alpha fair value

Locked

Current Price

$16.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.